e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Clearmind Medicine Inc. - Common Shares
(NQ:
CMND
)
0.8137
+0.0767 (+10.41%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
105,803
Open
0.7200
Bid (Size)
0.7551 (1,300)
Ask (Size)
0.8100 (600)
Prev. Close
0.7370
Today's Range
0.7200 - 0.8400
52wk Range
0.5949 - 52.40
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
March 27, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
March 19, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Performance
YTD
-59.1%
-59.1%
1 Month
-30.5%
-30.5%
3 Month
-63.2%
-63.2%
6 Month
-98.1%
-98.1%
1 Year
-98.1%
-98.1%
More News
Read More
Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies
March 17, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
March 13, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
March 11, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
March 10, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
March 04, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
February 09, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
February 06, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI
February 06, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments
February 03, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025
January 20, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100
January 14, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement
December 31, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth
December 24, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
December 16, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment
December 12, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
December 12, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Top movers analysis one hour before the close of the markets on 2025-12-11: top gainers and losers in today's session.
↗
December 11, 2025
Via
Chartmill
Top stock movements in today's session.
↗
December 11, 2025
Via
Chartmill
The market is filled with gapping stocks in Thursday's session.
↗
December 11, 2025
Via
Chartmill
Get insights into the top gainers and losers of Thursday's pre-market session.
↗
December 11, 2025
Via
Chartmill
Stay updated with the stocks that are on the move in today's after-hours session.
↗
December 10, 2025
Via
Chartmill
Clearmind Medicine Announces 1-for-40 Reverse Share Split
December 10, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
December 05, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is Clearmind Medicine Inc. - Common Shares publicly traded?
Yes, Clearmind Medicine Inc. - Common Shares is publicly traded.
What exchange does Clearmind Medicine Inc. - Common Shares trade on?
Clearmind Medicine Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Clearmind Medicine Inc. - Common Shares?
The ticker symbol for Clearmind Medicine Inc. - Common Shares is CMND on the Nasdaq Stock Market
What is the current price of Clearmind Medicine Inc. - Common Shares?
The current price of Clearmind Medicine Inc. - Common Shares is 0.8137
When was Clearmind Medicine Inc. - Common Shares last traded?
The last trade of Clearmind Medicine Inc. - Common Shares was at 03/27/26 04:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.